Schmölzer G, Urlesberger B, Reiterer F, Haim M, Kutschera J, Resch B, Müller W
Klinische Abteilung für Neonatologie, Universitätsklinik für Kinder- und Jugendheilkunde Graz, Osterreich.
Klin Padiatr. 2003 Sep-Oct;215(5):257-61. doi: 10.1055/s-2003-42668.
Inhaled nitric oxide (iNO) is used as a vasodilator in pulmonary hypertension (PH) of the newborn infant.
Retrospective analysis of patients, who were treated at our department with iNO in the period from 1994-2001. Response was defined as an increase of the paO (2)/FiO (2) Ratio > or = 20 % and/or a decrease of the oxygenation index (OI) >/= 20 % after 2 h (early response), and consecutively after 24 h (late response). The patients were divided into a) primary persistent pulmonary hypertension of the newbom (PPHN), or b) pulmonary hypertension secondary to meconium aspiration syndrome (MAS), sepsis or congenital diaphragmatic hernia (CDH).
Between 1994 and 2001 we treated 47 patients with iNO at our neonatal intensive care unit. We included 16 (35 %) preterm infants (GA 34,5 [25 - 37] weeks, GG 2061 [680 - 3410] g) (Median/Range) and 31 (65 %) newbom (GA 40 [38 - 42] weeks, GG 3510 [2550 - 4560] g). 18 (38 %) patients suffered from primary PPHN, 29 (62 %) from secondary PPHN (14 MAS [30 %], 8 sepsis [17 %], 4 CDH [8 %]). 8 (50 %) preterm and 20 (64 %) term infants showed a positive iNO response after 2 h, again 8 (50 %) preterm and 20 (64%) term infants showed a positive iNO response after 24 h. There was neither a significant difference between term and preterm infants at 2 h, nor at 24 h. Between 2 h and 24 h 10 patients changed in their response to iNO. 5 (18 %) patients with early response showed a significant degradation after 24 h, whereas 5 (26 %) of the patients without early response showed a significant improvement of the oxygenation alter 24 h. Alltogether 13 (72 %) patients with PPHN, 8 (57 %) with MAS, 2 (50 %) with CDH, 4 (50 %) with sepsis showed a positive iNO response after 24 h. In regard to the oxygenation parameters at start of iNO-therapy, the patients with early response did not differ from the patient without response (median OI: 20,0 versus 21,8, median paO (2)/FiO (2) Ratio: 59,3 versus 55,0 mmHg at the start of the iNO therapy).
In regard to iNO response, there was no significant difference between term and preterm infants. Due to the changing response, a positive iNO-response after 2 h had no predictive value for the further prognosis of the oxygenation situation under iNO therapy.
吸入一氧化氮(iNO)在新生儿肺动脉高压(PH)中用作血管扩张剂。
对1994年至2001年期间在我科接受iNO治疗的患者进行回顾性分析。反应定义为2小时后(早期反应)动脉血氧分压(PaO₂)/吸入氧分数值(FiO₂)比值增加≥20%和/或氧合指数(OI)降低≥20%,并在24小时后(晚期反应)持续出现上述情况。患者分为a)新生儿原发性持续性肺动脉高压(PPHN),或b)胎粪吸入综合征(MAS)、败血症或先天性膈疝(CDH)继发的肺动脉高压。
1994年至2001年期间,我们在新生儿重症监护病房对47例患者使用了iNO。其中包括16例(35%)早产儿(胎龄34.5[25 - 37]周,出生体重2061[680 - 3410]克)(中位数/范围)和31例(65%)足月儿(胎龄40[38 - 42]周,出生体重3510[2550 - 4560]克)。18例(38%)患者患有原发性PPHN,29例(62%)患有继发性PPHN(14例MAS[30%],8例败血症[17%],4例CDH[8%])。8例(50%)早产儿和20例(64%)足月儿在2小时后显示iNO反应阳性,同样8例(50%)早产儿和20例(64%)足月儿在24小时后显示iNO反应阳性。在2小时和24小时时,足月儿和早产儿之间均无显著差异。在2小时至24小时之间,有10例患者对iNO的反应发生了变化。5例(18%)早期反应患者在24小时后显示明显恶化,而5例(26%)无早期反应患者在24小时后氧合情况显示明显改善。总共13例(72%)PPHN患者、8例(57%)MAS患者、2例(50%)CDH患者、4例(50%)败血症患者在24小时后显示iNO反应阳性。关于iNO治疗开始时的氧合参数,早期反应患者与无反应患者无差异(iNO治疗开始时,OI中位数:20.0对21.8,PaO₂/FiO₂比值中位数:59.3对55.0 mmHg)。
关于iNO反应,足月儿和早产儿之间无显著差异。由于反应变化,2小时后的阳性iNO反应对iNO治疗下氧合情况的进一步预后无预测价值。